Factor | Single Variable Analysis | Multivariable Analysis | ||
---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | |
Age, yrs | 0.96 (0.91–1.01) | 0.089 | ||
Disease category* | 1.84 (1.09–3.12) | 0.023 | 2.24 (0.97–5.18) | 0.060 |
Sex** | 3.66 (1.22–11.0) | 0.021 | ||
Weight, kg | 1.05 (1.01–1.10) | 0.016 | 1.06 (1.01–1.12) | 0.042 |
ESR, mm/h | 0.98 (0.95–1.00) | 0.060 | ||
CRP, mg/l | 0.99 (0.97–1.01) | 0.281 | ||
DAS | 0.65 (0.40–1.07) | 0.089 | ||
DAS28-CRP | 0.89 (0.58–1.28) | 0.616 | ||
Fatigue, 0–10 scale | 0.96 (0.75–1.22) | 0.732 | ||
GVAS, 0–100 mm | 0.92 (0.72–1.17) | 0.492 | ||
HAQ, 0–3 scale | 0.67 (0.30–1.48) | 0.320 | ||
Pain, 0–10 scale | 1.16 (0.92–1.45) | 0.203 | ||
TJC, 0–28 joints | 0.99 (0.93–1.05) | 0.659 | ||
SJC, 0–28 joints | 1.02 (0.95–1.09) | 0.645 | ||
Stiffness, min | 1.00 (0.99–1.01) | 0.500 | ||
Bone ALP, μg/l | 0.87 (0.77–0.99) | 0.031 | 0.76 (0.620–0.94) | 0.010 |
PINP, μg/l | 0.97 (0.94–0.99) | 0.021 | ||
OC[1–49], μg/l | 0.92 (0.83–1.02) | 0.099 | ||
CTX-I, μg/l | 0.32 (0.00–0.48) | 0.013 | ||
NTX-I, nmolBCE/mmol Cr | 0.97 (0.95–0.99) | 0.026 | ||
fDPD, nmol/mmol Cr | 0.88 (0.77–1.01) | 0.070 |
↵* If disease category is psoriatic arthritis.
↵** If sex is male. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28-CRP: 28-joint Disease Activity Score using the CRP; GVAS: global visual analog scale (0 = worst imaginable health state to 100 = best imaginable health state); HAQ: Health Assessment Questionnaire scale (0 = no difficulty to 3 = unable to perform activity); TJC: tender joint count; SJC: swollen joint count; serum bone ALP: bone-specific alkaline phosphatase; serum PINP: procollagen type-I N-propeptide; serum OC[1–49]: intact osteocalcin; serum CTX-I: C-terminal cross-linking telopeptide of type-I collagen; urine NTX-I: N-terminal cross-linking telopeptide of type-I collagen; urine fDPD: free deoxypyridinoline crosslinks;